fda pulls semaglutide issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA is moving to restrict

DOI: 10.1136/bmj-2025-085304 Funding: National Institute of Health and Care Research (NIHR) Oxford Biomedical Research Centre Never miss a breakthrough: Join the SciTechDaily newsletter

Call us from 9:30am to 4:00pm

31 Lastly, a longer-acting synthetic derivative of GLP-1, liraglutide, is in the pipeline

Clinical studies consistently show that most people who stop semaglutide or tirzepatide regain a substantial portion of the weight they lost and research suggests the regained weight is disproportionately fat rather than the lean muscle mass that may have been lost during treatment

Eva Wolf: Id say dont give up hope if you cant get a GLP-1